• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Insulet looks north of the border with GlaxoSmithKline deal

Insulet looks north of the border with GlaxoSmithKline deal

March 2, 2011 By MassDevice staff

Insulet

UPDATED 3/3/2011 10:20 a.m.

Insulet Corp. (NSDQ:PODD) inked a Canadian distribution deal with GlaxoSmithKline plc (NYSE:GSK) for its OmniPod insulin management system.

The deal gives the British pharma giant — stung by recent problems with its Avandia diabetes drug — exclusive rights to market and sell Bedford, Mass.-based Insulet’s OmniPod system north of the border.

GSK, which was Insulet’s first choice for Canadian distribution, brings a level of scale and frequency that the company would struggle to be able to match, Insulet CFO Brian Roberts told MassDevice.

Financial terms of the agreement were not disclosed. Independent diabetes analyst David Kliff said the earnings impact for Insulet would probably not be immediate.

Kliff, who publishes the Diabetic Investor, writes that the deal could be Glaxo’s attempt to improve its reputation in the diabetes market after the Avandia debacle. For Insulet, the deal is an expansion into a small but important market, according to Kliff.

The company focuses on Type I diabetes. In Canada, that means 200,000 to 250,000 patients, of which about 10 percent use insulin pumps, Roberts said.

It’s hard to say how much of that market Insulet can carve out for itself, but the company has taken a 7 percent share of the U.S. market about two years after completing the build-out of its national sales force, he added.

"If you put that in comparison with companies like Medtronic, which have the lion’s share, they’ve been at it for 25 years," he said.

To compete, Insulet focuses on patients who have never used an insulin pump device; about 70 to 75 percent of the company’s customers are "first-time pumpers," Roberts said.

The GSK deal is also an expansion of Insulet’s international distribution operation. In January 2010, it signed a five-year, $100 million deal with Ypsomed Holding AG (SWP:YPSN) to distribute the OmniPod in 11 countries, including China.

Insulet reported higher sales but wider losses during the fourth quarter. Annual losses, however, narrowed by 16 percent, and the company made a final, $33 million payment on its $60 million credit line with Deerfield Partners in December 2010, more than nine months ahead of schedule.

Roberts expects Insulet to be "operating cash break-even," which means they’re not covering their interest, by the beginning of 2012, and reach profitability by the end 2012 or the beginning of 2013.

The company is hoping for Food & Drug Administration 510(k) clearance for its cheaper-to-produce, next-generation OmniPod by the end of this year, which would bring a significant gross margin improvement, Roberts said. That device would cost about a third less to make, he added, noting that if the company does win FDA clearance it plans to bulk up its sales operation.

Kliff pointed out that the "key to Insulet’s future" is the lowering its cost-of-goods-sold.

The additional volume provided by the Canada deal should help in that regard, he writes, but the new product and a larger sales force can’t hurt the company’s prospects as well.

PODD shares closed the day at $17.65, up slightly less than 1 percent.

Filed Under: News Well Tagged With: Distribution, Insulet, Insulin Management

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy